Gain Therapeutics up as compounds show promise in Gaucher and Parkinson's Disease

Gain Therapeutics

08/09/2021 13:03

** Shares of drug developer  GANX.O  rise 39.1% to $10.99
premarket
    ** Co says its two lead compounds, GT-02287 and GT-02329,
showed positive effects in Gaucher and Parkinson's Disease in
lab study  urn:newsml:reuters.com:*:nGNX6s2FDD
    ** Gaucher disease is inherited condition that causes fatty
substances to build up in bone marrow, liver and spleen;
Parkinson's Disease is a progressive nervous system disorder
    ** Study, conducted at University of Maryland School of
Medicine, used stem cells derived from patients with Parkinson's
disease and Gaucher Disease
    ** Compounds increased levels of GCase protein, an enzyme
whose deficiency leads to Gaucher Disease as well as decreased
levels of α-synuclein-p129, a protein whose accumulation and
aggregation is believed to be cause of Parkinson's Disease
    ** Co anticipates initiating IND-enabling studies for
Gaucher/Parkinson's Disease in Q4; IND-enabling studies are
conducted to secure approval to start first-in-human clinical
trials of drugs
    ** Stock has lost ~29.5% since March 18 IPO

 (Reporting by Mrinalika Roy in Bengaluru)
 ((mrinalika.roy@thomsonreuters.com; within U.S. +1 646 223
8780, outside U.S. +91 806749 8325;))